Risk Considerations on Developing a Continuous Crystallization System for Carbamazepine
Open Access
- 8 July 2017
- journal article
- review article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 21 (7) , 1021-1033
Abstract
Continuous manufacturing (CM) is an emerging technology in the pharmaceutical manufacturing sector, and the understanding of the impact on product quality is currently evolving. As the final purification and isolation step, crystallization has a significant impact on the final physicochemical properties of drug substance and is considered a critical process step in achieving the continuous manufacturing of drug substances. Although many publications previously focused on various innovative techniques to continuously make crystals with desired properties, engineering difficulties such as system design, automation, and integration with process analytical technology (PAT) tools have not been thoroughly discussed. Here, we focus on how to develop a continuous crystallization system, from the perspective of process engineering, and the related risk considerations on product quality. Specifically, we designed and built an automated two-stage mixed suspension mixed product removal (MSMPR) crystallization platform for a model compound (carbamazepine, CBZ) that exhibits multiple polymorphs. The crystallization process includes the integration of PAT tools (online Raman microscopy and focused beam reflectance microscopy, FBRM) for real-time monitoring. A series of case studies were done to evaluate the performance of the continuous system and PAT tools. Specifically, the drawing schemes, slurry transport, and variations on process variables are considered as the three key risk areas for continuous crystallization process development. Our proof-of-concept continuous crystallization system uses feedback/feedforward controls to achieve constant levels in crystallizers, a centralized automation program coded in LabVIEW, and PAT monitoring for polymorphs and particle size distribution (Raman and FBRM). To the best of our knowledge, this is also the first study on continuous crystallization of carbamazepine for form III and its polymorphic transition (between form II and form III).Keywords
Funding Information
- U.S. Food and Drug Administration
This publication has 41 references indexed in Scilit:
- Process Intensification through Continuous Spherical Crystallization Using a Two-Stage Mixed Suspension Mixed Product Removal (MSMPR) SystemCrystal Growth & Design, 2015
- Modernizing Pharmaceutical Manufacturing: from Batch to Continuous ProductionJournal of Pharmaceutical Innovation, 2015
- Achieving Continuous Manufacturing for Final Dosage Formation: Challenges and How to Meet Them May 20–21 2014 Continuous Manufacturing SymposiumJournal of Pharmaceutical Sciences, 2015
- Application of Continuous Crystallization in an Integrated Continuous Pharmaceutical Pilot PlantCrystal Growth & Design, 2014
- Development of a Multi-Step Synthesis and Workup Sequence for an Integrated, Continuous Manufacturing Process of a PharmaceuticalOrganic Process Research & Development, 2014
- End‐to‐End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage FormationAngewandte Chemie International Edition, 2013
- Development of Continuous Crystallization Processes Using a Single-Stage Mixed-Suspension, Mixed-Product Removal Crystallizer with RecycleCrystal Growth & Design, 2012
- Continuous Crystallization of Aliskiren HemifumarateCrystal Growth & Design, 2012
- Development of a Photochemical Microfluidics PlatformJournal of Flow Chemistry, 2011
- Development of an Automated Microfluidic Reaction Platform for Multidimensional Screening: Reaction Discovery Employing Bicyclo[3.2.1]octanoid ScaffoldsThe Journal of Organic Chemistry, 2009